dc.contributor.author | Villalobos Jorge, Carlos | |
dc.contributor.author | Sobradillo Luengo, Diego | |
dc.contributor.author | Hernández Morales, Miriam | |
dc.contributor.author | Núñez Llorente, Lucía | |
dc.date.accessioned | 2021-01-15T13:53:41Z | |
dc.date.available | 2021-01-15T13:53:41Z | |
dc.date.issued | 2017 | |
dc.identifier.citation | Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2017, vol. 1864, n. 6. p. 843-849 | es |
dc.identifier.issn | 0167-4889 | es |
dc.identifier.uri | http://uvadoc.uva.es/handle/10324/45028 | |
dc.description | Producción Científica | es |
dc.description.abstract | Colorectal cancer (CRC) is the third most frequent form of cancer and the fourth leading cause of cancer-related death in the world. Basic and clinical data indicate that aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) may prevent colon cancer but mechanisms remain unknown. Aspirin metabolite salicylate and other NSAIDs may inhibit tumor cell growth acting on store-operated Ca2 + entry (SOCE), suggesting an important role for this pathway in CRC. Consistently, SOCE is emerging as a novel player in different forms of cancer, including CRC. SOCE and store-operated currents (SOCs) are dramatically enhanced in CRC while Ca2 + stores are partially empty in CRC cells. These features may contribute to CRC hallmarks including enhanced cell proliferation, migration, invasion and survival. At the molecular level, enhanced SOCE and depleted stores are mediated by overexpression of Orai1, Stromal interaction protein 1 (STIM1) and Transient receptor protein channel 1 (TRPC1) and downregulation of STIM2. In normal colonic cells, SOCE is mediated by Ca2 +-release activated Ca2 + channels made of STIM1, STIM2 and Orai1. In CRC cells, SOCE is mediated by different store-operated currents (SOCs) driven by STIM1, Orai1 and TRPC1. Loss of STIM2 contributes to depletion of Ca2 + stores and enhanced resistance to cell death in CRC cells. Thus, SOCE is a novel key player in CRC and inhibition by salicylate and other NSAIDs may contribute to explain chemoprevention activity. | es |
dc.format.mimetype | application/pdf | es |
dc.language.iso | eng | es |
dc.publisher | Elsevier | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject.classification | Colorectal cancer | es |
dc.subject.classification | Cáncer colorrectal | es |
dc.subject.classification | Calcium | es |
dc.subject.classification | Calcio | es |
dc.subject.classification | Aspirin | es |
dc.subject.classification | Aspirin | es |
dc.title | Calcium remodeling in colorectal cancer | es |
dc.type | info:eu-repo/semantics/article | es |
dc.rights.holder | © 2017 Elsevier | es |
dc.identifier.doi | 10.1016/j.bbamcr.2017.01.005 | es |
dc.relation.publisherversion | https://www.sciencedirect.com/science/article/pii/S0167488917300071?via%3Dihub | es |
dc.peerreviewed | SI | es |
dc.description.project | Ministerio de Economía, Industria y Competitividad (grant BFU2015-70131R) | es |
dc.description.project | Junta de Castilla y León (grant BIO/VA46/14) | es |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.type.hasVersion | info:eu-repo/semantics/publishedVersion | es |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internacional